Neurosurgical Oncology Ward 5

      Beijing Tiantan Hospital  Neurosurgical Oncology Ward 5(Glioma Treatment Center of Beijing Tiantan Hospital), also known as the Glioma Clinical Treatment and Research Center of Capital Medical University, was established in September 2004 under the initiative and organization of Academician Zhongcheng Wang and is the first glioma treatment center in China that integrates surgery, radiotherapy, chemotherapy, and drug clinical trials. The center is an academic and innovative team led by Professor Tao Jiang, which is a combination of young and middle-aged, multidisciplinary talents, with members consisting of neurosurgery, neuro-oncology, tumor radiotherapy, neuro-imaging, neuropathology, molecular pathology, neuro-electrophysiology physicians, as well as digital medicine researchers, nursing staff and technicians. There are three full professors, two associate professors, five chief physicians, three deputy chief physicians, and two attending physicians. In addition, there are three doctoral supervisors and four master's supervisors. The scope of treatment mainly includes common cranial tumors such as glioma, meningioma, metastatic brain cancer, pituitary tumor, auditory neuroma, etc. The specialty of the ward is to perform awakening surgery for glioma in the functional area and MDT multidisciplinary treatment for neuro-oncology. At present, the annual glioma surgery volume reaches more than 600 cases. The center is mainly dedicated to basic clinical translation, multidisciplinary cross-fertilization, new drug clinical trials, and evidence-based medical research in glioma.

      The center initiated the creation of the China/Asia Glioma Genome Atlas Project (CGGA/AGGA), serves as the Chinese chairman of the Global Glioma Adaptive Clinical Innovation Trial System (GBM AGILE), and holds the China Glioma Academic Conference, the Jinling International Forum on Glioma, and the National Symposium on Molecular Pathology and Comprehensive Treatment of Glioma every year. The center also cooperates and exchanges with famous brain tumor clinical research centers abroad, such as MD Anderson Cancer Center, the University of California, San Francisco, and Minnesota State University. The center has been awarded the Second Prize of National Science and Technology Progress and several provincial and ministerial science and technology awards, led the development of the National Health Care Commission's Glioma Diagnostic and Treatment Protocol 2018 Edition, established the first international full-grade glioma fusion gene profile, and developed the MET-specific single-target inhibitor PLB-1001, which has completed the phase I clinical trial and received the PCT US patent. The research results were published in the internationally renowned journal CELL. The related achievements were awarded the top ten advances in bioinformatics in China in 2021 and the finalist of the Zhongguancun International Frontier Science and Technology Innovation Competition.

      The center will build on the existing advantages of the discipline, introduce advanced technology nationally and internationally, innovate independently, and strive to build a standardized and individualized comprehensive diagnosis and treatment center for glioma, which is the top in China and the first class in the world.

Departmental Features

      Relying on advanced instrumentation and treatment concepts, the center uses advanced technologies such as wake-up anesthesia, electrophysiological monitoring, and functional navigation to develop individualized and precise treatment strategies for patients. In the preoperative stage, patients are evaluated comprehensively. Individualized surgical plans are formulated by applying the fine localization and protection plan for critical functional areas of the brain; in the intraoperative stage, the "skeleton" resection style of glioma and the precise surgical technique system for functional areas of the brain are applied to remove the tumor to the maximum extent safely; in the postoperative stage, the individualized treatment strategy for glioma based on the Chinese population is applied. After surgery, the patient was treated with an individualized treatment strategy based on the Chinese people. An individualized radiotherapy plan was formulated for the patient effectively and reasonably. As a result, the patient's survival period is significantly prolonged, the rate of long-term postoperative dysfunction is significantly reduced, and the quality of survival is improved substantially, maintaining the advanced international level in the comprehensive treatment of glioma.

Treatment Scope

      This ward's treatment scope mainly includes glioma, meningioma, metastatic brain cancer, pituitary tumor, auditory neuroma, and other common craniocerebral tumors. The ward's specialty is functional area glioma awakening surgery and neuro-oncology MDT multidisciplinary comprehensive treatment. At present, the annual glioma surgery volume reaches more than 600 cases. The team is mainly devoted to basic clinical translation, multidisciplinary cross-fertilization, new drug clinical trials, and evidence-based medical research in glioma.

Neurosurgical Oncology Ward 5 Beijing Tiantan Hospital Neurosurgical Oncology Ward 5(Glioma Treatment Center of Beijing Tiantan Hospital), also known as the Glioma Clinical Treatment and Research Center of Capital Medical University, was established in September 2004 under the initiative and organization of Academician Zhongcheng Wang and is the first glioma treatment center in China that in…